| Literature DB >> 28288666 |
Riikka Johanna Niemi1, Sami Kristian Saarelainen2, Tiina Hannele Luukkaala3, Johanna Unelma Mäenpää2,4.
Abstract
BACKGROUND: Preoperative evaluation of ovarian tumors is challenging. This study was undertaken to evaluate the performance of conventional two-dimensional (2D) ultrasound and CA125 in predicting malignant or benign nature of pelvic masses, and to investigate if three-dimensional power Doppler (3DPD) ultrasound provides any added value. Ninety-six postmenopausal and four perimenopausal women with supposed ovarian tumors were examined by standardized 2D and 3DPD ultrasounds preoperatively. The tumors were evaluated using the risk of malignancy index (RMI), International Ovarian Tumors Analysis (IOTA) group simple rules, expert opinion, IOTA logistic regression model 2 (LR2) and 3D vascular indices, and were postoperatively compared to histopathological results.Entities:
Keywords: Expert opinion; IOTA LR2; IOTA simple rules; Ovarian cancer; Ovarian tumor; Power doppler; Three-dimensional ultrasound
Mesh:
Substances:
Year: 2017 PMID: 28288666 PMCID: PMC5348789 DOI: 10.1186/s13048-017-0309-4
Source DB: PubMed Journal: J Ovarian Res ISSN: 1757-2215 Impact factor: 4.234
Histology of the tumors
| Histologic type | Number | Percent |
|---|---|---|
| Benign | 66 | (67.3) |
| Serous cystadenoma/adenofibroma | 39 | |
| Fibroma/thecoma | 5 | |
| Teratoma | 7 | |
| Brenner tumor | 1 | |
| Endometrioma | 3 | |
| Mucinous cystadenoma | 3 | |
| Serous/hemorrhagic cyst | 7 | |
| Bizarre leiomyoma | 1 | |
| Malignant | 32 | (32.7) |
| Epithelial tumors | ||
| Serous | ||
| High grade | 9 | |
| Low grade | 3 | |
| Borderline | 5 | |
| Mucinous | ||
| Adenocarcinoma | 3 | |
| Borderline | 2 | |
| Clear cell carcinoma | 1 | |
| Carcinosarcoma | 2 | |
| Non-epithelial tumors | ||
| Granulosa cell tumor | 4 | |
| Sertoli-Leydig cell tumor | 1 | |
| Metastatica | 2 | |
| Total | 98 | (100.0) |
aPrimary tumors: sigmoid carcinoma and carcinoma of the appendix
Diagnostic performances of different methods at various cut-off values in detecting ovarian malignancy
| Diagnostic method | Sensitivity | 95% CI | Specificity | 95% CI | PPV | 95% CI | NPV | 95% CI | Accuracy % |
|---|---|---|---|---|---|---|---|---|---|
| Serum CA125 (kU/L) → Area under the ROC curve = 0.80 | |||||||||
| 24 | 71.9 | 53.3–86.3 | 78.8 | 67.0–87.9 | 62.2 | 44.8–77.5 | 85.3 | 73.8–93.0 | 76.5 |
| 35 | 59.4 | 40.6–76.3 | 84.9 | 73.9–92.5 | 65.5 | 45.7–82.1 | 81.2 | 69.9–89.6 | 76.5 |
| RMI → Area under the ROC curve = 0.81 | |||||||||
| 200 | 71.9 | 53.3–86.3 | 80.3 | 68.7–89.1 | 63.9 | 46.2–79.2 | 85.5 | 74.2–93.1 | 77.6 |
| 220 | 71.9 | 53.3–86.3 | 83.3 | 72.1–91.4 | 67.7 | 49.5–82.6 | 85.9 | 75.0–93.4 | 79.6 |
| Simple rules with expert opiniona | 90.6 | 75.0–98.0 | 84.6 | 73.9–92.5 | 74.4 | 57.9–87.0 | 94.9 | 85.9–98.9 | 86.7 |
| Expert opinion | 87.5 | 71.0–96.5 | 92.4 | 83.2–97.5 | 84.6 | 68.1–94.9 | 93.9 | 85.0–98.3 | 90.8 |
| Tumor vascularityb | 90.6 | 75.0–98.0 | 77.3 | 65.3–86.7 | 65.9 | 50.1–79.5 | 94.4 | 84.6–98.8 | 81.6 |
| LR2 (%) → Area under the ROC curve = 0.93 | |||||||||
| 10 | 100.0 | 89.1–100.0 | 36.4 | 24.9–49.1 | 43.2 | 31.8–55.3 | 100.0 | 85.8–100.0 | 57.1 |
| 25 | 90.6 | 75.0–98.0 | 77.3 | 65.3–86.7 | 65.9 | 50.1–79.5 | 94.4 | 84.6–98.8 | 81.6 |
| 43 | 81.3 | 63.6–92.8 | 90.9 | 81.3–96.6 | 81.3 | 63.6–92.8 | 90.9 | 81.3–96.6 | 87.8 |
IOTA International Ovarian Tumor Analysis; CI Confidential interval; PPV Positive predictive value; NPV Negative predictive value; ROC Receiver operating characteristics; RMI Risk of malignancy index; LR2 Logistic regression model 2
aTwo-step strategy: as a result of inconclusive findings by simple rules, the expert evaluates the tumor
bTwo-dimensional ultrasound vascular score 1-2 vs 3-4
Diagnostic performances of three-dimensional power Doppler indices at different cut-off values in detecting ovarian malignancy
| 3DPD indices | Sensitivity | 95% CI | Specificity | 95% CI | PPV % | 95% CI | NPV % | 95% CI | Accuracy |
|---|---|---|---|---|---|---|---|---|---|
| VI (%) → Area under the ROC curve = 0.86 | |||||||||
| 1.00 | 67.7 | 48.6–83.3 | 90.9 | 81.3–96.6 | 77.8 | 57.7–91.4 | 85.7 | 75.3–92.9 | 83.5 |
| FI → Area under the ROC curve = 0.72 | |||||||||
| 30 | 83.9 | 66.3–94.6 | 51.5 | 38.9–64.0 | 44.8 | 31.7–58.5 | 87.2 | 72.6–95.7 | 61.9 |
| VFI → Area under the ROC curve = 0.87 | |||||||||
| 0.31 | 71.0 | 52.0–85.8 | 89.4 | 79.4–95.6 | 75.9 | 56.5–89.7 | 86.8 | 76.4–93.8 | 83.5 |
3DPD Three-dimensional power Doppler; CI Confidential interval; PPV Positive predictive value; NPV Negative predictive value; ROC Receiver operating characteristics; VI Vascularization index; FI Flow index; VFI Vascularization flow index
Interobserver agreement between two experts using three-dimensional power Doppler (3DPD) indices
| 3DPD indices | Expert opinion 1 | Expert opinion 2 |
|
|---|---|---|---|
| Median | Median | ||
| VI | 0.337 (0.069–1.098) | 0.259 (0.066–0.894) | 0.151 |
| FI | 31.796 (25.308–35.821) | 31.693 (26.351–36.638) | 0.839 |
| VFI | 0.112 (0.019–0.397) | 0.079 (0.019–0.292) | 0.257 |
3DPD Three-dimensional power Doppler; VI Vascularization index; FI Flow index; VFI Vascularization flow index
aCalculated by related-samples Wilcoxon signed rank test
Diagnostic performances of combined methods to detect malignancy at specific cut-off values
| Developed method | Sensitivity | 95% CI | Specificity | 95% CI | PPV | 95% CI | NPV | 95% CI | Accuracy |
|---|---|---|---|---|---|---|---|---|---|
| RMI > 200 and VFI > 0.31 | 51.6 | 33.1–69.9 | 95.5 | 87.3–99.1 | 84.2 | 60.4–96.6 | 80.8 | 70.3–88.8 | 81.4 |
| Simple rules with expert opiniona and VFI > 0.31 | 71.0 | 52.0–85.8 | 95.5 | 87.3–99.1 | 88.0 | 68.8–97.5 | 87.5 | 77.6–94.1 | 86.7 |
| LR2 > 25 and VFI > 0.31 | 64.5 | 45.4–80.8 | 97.0 | 89.5–99.6 | 90.9 | 70.8–98.9 | 85.3 | 75.3–92.4 | 86.5 |
IOTA International Ovarian Tumor Analysis; CI Confidential interval; PPV Positive predictive value; NPV Negative predictive value; RMI Risk of malignancy index; VFI Vascularization flow index; LR2 Logistic regression model 2
aTwo step-strategy: As a result of inconclusive by simple rules, the expert evaluates the tumor